Trevi Therapeutics to Participate in Upcoming February Investor Conferences

NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in February.Piper Sandler Biopharma Mogul SummitFebruary 2-4, 2025, Park City, UtahTrevi Repres ...